GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » Intangible Assets

XTLB (XTL Biopharmaceuticals) Intangible Assets : $7.08 Mil (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. XTL Biopharmaceuticals's intangible assets for the quarter that ended in Sep. 2024 was $7.08 Mil.


XTL Biopharmaceuticals Intangible Assets Historical Data

The historical data trend for XTL Biopharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Intangible Assets Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.38 0.38 0.38 0.38

XTL Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.38 0.38 0.38 7.08

XTL Biopharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


XTL Biopharmaceuticals  (NAS:XTLB) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


XTL Biopharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989